Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12362807 | 0.89 | CHRM2 (0.56) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL12933270 | 0.87 | TDP1 (0.56) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL20963020 | 0.85 | GLS (0.49) | GLSACHECHRM2MEN1CYP1A2 | |
| SCHEMBL4395759 | 0.85 | GLS (0.52) | GLSACHECHRM2MEN1CYP1A2 | |
| SCHEMBL25488435 | 0.83 | HPGD (0.53) | GLSMEN1KMT2A | |
| SCHEMBL10243309 | 0.83 | MAOB (0.56) | GLSACHE | |
| SCHEMBL13625081 | 0.83 | HEXA (0.55) | GLSACHE | |
| SCHEMBL18409910 | 0.82 | GLS (0.49) | GLSACHECHRM2MEN1CYP1A2 | |
| SCHEMBL21744520 | 0.82 | CHRM2 (0.49) | GLSACHECHRM2MEN1CYP1A2 | |
| SCHEMBL9430060 | 0.82 | RAB9A (0.50) | GLSACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319289-B2 | 5-hydroxy pyridine-based compound for use as P2X1 and P2X3 receptor antagonist and pharmaceutical composition comprising same | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-05-03 | — | — | US | disclosed |
| US-20200131131-A1 | NOVEL 5-HYDROXY PYRIDINE-BASED COMPOUND FOR USE AS P2X1 AND P2X3 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-04-30 | — | — | US | disclosed |
| US-20180224422-A1 | CONTROLLED TUNNEL GAP DEVICE FOR SEQUENCING POLYMERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-08-09 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-9810681-B2 | Controlled tunnel gap device for sequencing polymers | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160097759-A1 | CONTROLLED TUNNEL GAP DEVICE FOR SEQUENCING POLYMERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2016-04-07 | — | — | US | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20130045935-A1 | FLAVONOID DIMERS AND THEIR USE | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2013-02-21 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-7365093-B2 | Endothelin antagonists | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | GLS 396/4885ACHE 2598/4885CHRM2 1854/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | GLS 396/4885ACHE 2598/4885CHRM2 1854/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | GLS 214/4885ACHE 1511/4885CHRM2 4698/4885 |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | EPCAM, SOD1, SBDS | GLS 2457/4885ACHE 1014/4885CHRM2 1367/4885 |
| US-11319289-B2 | 5-hydroxy pyridine-based compound for use as P2X1 and P2X3 receptor antagonist and pharmaceutical composition comprising same | P2RX5, P2RX3, P2RX1 | GLS 3310/4885ACHE 960/4885CHRM2 1091/4885 |
| US-20200131131-A1 | NOVEL 5-HYDROXY PYRIDINE-BASED COMPOUND FOR USE AS P2X1 AND P2X3 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | P2RX5, P2RX3, P2RX1 | GLS 3134/4885ACHE 995/4885CHRM2 1033/4885 |
| US-20130045935-A1 | FLAVONOID DIMERS AND THEIR USE | DHFR, CCNY, ETFB | GLS 792/4885ACHE 3938/4885CHRM2 4452/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | GLS 235/4885ACHE 1165/4885CHRM2 3436/4885 |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | CCNO, PTGDR, CCNE1 | GLS 396/4885ACHE 2598/4885CHRM2 1854/4885 |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | GLS 358/4885ACHE 472/4885CHRM2 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.